Cognitive Screening in Lung Cancer Patients
Recruiting
Observational Study
Lung Disease
NSCLC (Non-small Cell Lung Cancer)
SCLC
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- European Institute of Oncology · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
* Age ≥ 18 years
* Patients able to speak and read the local language(s) fluently
* Acceptance and signature of informed consent
Exclusion Criteria:
* Age ≥ 70
* Presence of brain metastases
* Patients with con…
Contacts
Lorenzo Conti
+390257489731
CONTACT